rss
Br J Ophthalmol 2006;90:922 doi:10.1136/bjo.2006.092262
  • Letter

Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function?

  1. F Ziemssen,
  2. M Warga,
  3. I M Neuhann,
  4. M Leitritz,
  5. S Biester,
  6. S Grisanti,
  7. K U Bartz-Schmidt,
  8. Tuebingen Bevacizumab Study Group
  1. University Eye Hospital, Tuebingen, Germany
  1. Correspondence to: Dr Focke Ziemssen University Eye Hospital, Schleichstrasse 12, D-72076 Tuebingen, Germany; focke.ziemssen{at}med.uni-tuebingen.de
  • Accepted 7 March 2006

Bevacizumab (Avastin), a humanised monoclonal anti-VEGF antibody originally developed for intravenous therapy of metastatic cancer, is now being used as off-label therapy in age related macular degeneration.1 The cost effective drug promises not only anti-angiogenic capabilities in neovascular eye disease, but has also anti-exudative effects by lowering transendothelial permeability of blood vessels.2

Blood-aqueous barrier (BAB) breakdown has been reported after intraocular application of lyophilised rhuFab formulations.3 Anterior chamber inflammation is one of the most frequently reported adverse events (19%) after pegaptanib injections.4 We wanted to post these safety issues for bevacizumab by objective detection of aqueous protein concentration.

Methods

The anterior chamber reaction was analysed in 60 patients receiving 1.25 mg of bevacizumab for age …

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.